Fig. 5
From: The path to the clinic: a comprehensive review on direct KRASG12C inhibitors
The diagram illustrates the nine small molecular inhibitors in registered clinical trials that directly target the KRASG12C mutant by binding to the switch II pocket (S-IIP). These inhibitors preferentially bind and stabilize RAS in the GDP-bound state, ultimately resulting in decreased signal transduction, especially by the RAF-MEK-ERK/MAP pathway, and thus preventing tumor progression